| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Tract Infections | 65 | 2025 | 318 | 14.660 |
Why?
|
| Bacteriuria | 35 | 2024 | 83 | 11.880 |
Why?
|
| Catheter-Related Infections | 31 | 2024 | 139 | 8.210 |
Why?
|
| Antimicrobial Stewardship | 18 | 2024 | 89 | 6.180 |
Why?
|
| Anti-Bacterial Agents | 59 | 2025 | 2592 | 6.070 |
Why?
|
| Urinary Catheterization | 26 | 2024 | 87 | 5.150 |
Why?
|
| Spinal Cord Injuries | 15 | 2025 | 285 | 4.380 |
Why?
|
| Urinary Catheters | 14 | 2024 | 26 | 3.650 |
Why?
|
| Cystitis | 7 | 2023 | 51 | 3.330 |
Why?
|
| Inappropriate Prescribing | 6 | 2019 | 42 | 2.500 |
Why?
|
| Catheters, Indwelling | 15 | 2020 | 158 | 2.430 |
Why?
|
| Urinalysis | 11 | 2025 | 70 | 2.210 |
Why?
|
| Asymptomatic Infections | 9 | 2019 | 38 | 2.110 |
Why?
|
| Cross Infection | 11 | 2020 | 344 | 2.080 |
Why?
|
| Anti-Infective Agents | 7 | 2023 | 277 | 1.910 |
Why?
|
| Escherichia coli | 17 | 2024 | 1034 | 1.810 |
Why?
|
| Health Knowledge, Attitudes, Practice | 9 | 2024 | 904 | 1.730 |
Why?
|
| Hospitals, Veterans | 7 | 2019 | 365 | 1.580 |
Why?
|
| Nursing Homes | 10 | 2021 | 107 | 1.570 |
Why?
|
| Bacteremia | 7 | 2018 | 430 | 1.520 |
Why?
|
| Fluoroquinolones | 7 | 2024 | 97 | 1.520 |
Why?
|
| Humans | 162 | 2025 | 133505 | 1.450 |
Why?
|
| Antibiosis | 5 | 2017 | 14 | 1.380 |
Why?
|
| Escherichia coli Infections | 8 | 2023 | 195 | 1.330 |
Why?
|
| Nonprescription Drugs | 3 | 2025 | 54 | 1.320 |
Why?
|
| Urine | 9 | 2021 | 92 | 1.300 |
Why?
|
| Veterans | 12 | 2025 | 1790 | 1.280 |
Why?
|
| Outpatients | 7 | 2025 | 277 | 1.280 |
Why?
|
| Bacterial Adhesion | 5 | 2012 | 109 | 1.250 |
Why?
|
| Enterobacteriaceae | 3 | 2018 | 41 | 1.250 |
Why?
|
| Biofilms | 6 | 2012 | 99 | 1.230 |
Why?
|
| Drug Utilization | 4 | 2020 | 170 | 1.210 |
Why?
|
| Unnecessary Procedures | 4 | 2019 | 60 | 1.160 |
Why?
|
| Infection Control | 10 | 2024 | 161 | 1.150 |
Why?
|
| Gram-Negative Bacterial Infections | 4 | 2022 | 92 | 1.110 |
Why?
|
| Catheters | 5 | 2023 | 89 | 1.080 |
Why?
|
| Attitude of Health Personnel | 5 | 2020 | 724 | 1.040 |
Why?
|
| Physicians | 5 | 2024 | 640 | 1.020 |
Why?
|
| Phage Therapy | 4 | 2023 | 39 | 0.990 |
Why?
|
| Bacteriophages | 6 | 2023 | 93 | 0.960 |
Why?
|
| Medical Audit | 3 | 2018 | 104 | 0.960 |
Why?
|
| Prostatitis | 2 | 2023 | 16 | 0.950 |
Why?
|
| Practice Patterns, Physicians' | 5 | 2024 | 774 | 0.910 |
Why?
|
| Female | 69 | 2025 | 71531 | 0.850 |
Why?
|
| Diagnostic Errors | 4 | 2016 | 349 | 0.830 |
Why?
|
| Natural Language Processing | 4 | 2016 | 71 | 0.820 |
Why?
|
| Aged | 39 | 2025 | 21572 | 0.820 |
Why?
|
| Catheterization, Peripheral | 3 | 2020 | 132 | 0.820 |
Why?
|
| United States | 27 | 2025 | 11759 | 0.810 |
Why?
|
| Internship and Residency | 4 | 2022 | 1250 | 0.810 |
Why?
|
| Drug Resistance, Bacterial | 7 | 2023 | 385 | 0.770 |
Why?
|
| Male | 62 | 2025 | 65641 | 0.760 |
Why?
|
| Middle Aged | 41 | 2025 | 29066 | 0.760 |
Why?
|
| Pyelonephritis | 1 | 2022 | 29 | 0.750 |
Why?
|
| Electronic Health Records | 5 | 2016 | 804 | 0.740 |
Why?
|
| Health Personnel | 3 | 2017 | 549 | 0.730 |
Why?
|
| Pyuria | 1 | 2021 | 6 | 0.720 |
Why?
|
| Adult | 44 | 2025 | 31766 | 0.720 |
Why?
|
| Hospitalization | 7 | 2025 | 1909 | 0.710 |
Why?
|
| Prosthesis-Related Infections | 2 | 2021 | 188 | 0.700 |
Why?
|
| Guideline Adherence | 5 | 2017 | 400 | 0.670 |
Why?
|
| Evidence-Based Medicine | 4 | 2017 | 681 | 0.640 |
Why?
|
| Medicine | 1 | 2021 | 106 | 0.640 |
Why?
|
| Inpatients | 4 | 2018 | 552 | 0.640 |
Why?
|
| Self Medication | 1 | 2019 | 21 | 0.630 |
Why?
|
| Treatment Failure | 3 | 2019 | 361 | 0.630 |
Why?
|
| Enterococcus faecalis | 3 | 2011 | 50 | 0.630 |
Why?
|
| Practice Patterns, Nurses' | 1 | 2019 | 11 | 0.620 |
Why?
|
| Drug Resistance, Microbial | 3 | 2021 | 199 | 0.620 |
Why?
|
| Enterobacteriaceae Infections | 2 | 2018 | 59 | 0.600 |
Why?
|
| Aged, 80 and over | 13 | 2020 | 7191 | 0.600 |
Why?
|
| Nitrofurantoin | 2 | 2023 | 10 | 0.580 |
Why?
|
| Algorithms | 3 | 2017 | 1730 | 0.580 |
Why?
|
| Surveys and Questionnaires | 14 | 2025 | 3989 | 0.570 |
Why?
|
| Practice Guidelines as Topic | 5 | 2020 | 1344 | 0.570 |
Why?
|
| Retrospective Studies | 20 | 2025 | 17564 | 0.560 |
Why?
|
| General Surgery | 1 | 2020 | 220 | 0.560 |
Why?
|
| Primary Health Care | 8 | 2025 | 804 | 0.550 |
Why?
|
| Oncologists | 1 | 2018 | 31 | 0.550 |
Why?
|
| Osteomyelitis | 2 | 2019 | 214 | 0.540 |
Why?
|
| Length of Stay | 3 | 2018 | 1392 | 0.540 |
Why?
|
| Hospitals | 7 | 2023 | 441 | 0.540 |
Why?
|
| Physicians, Women | 1 | 2018 | 52 | 0.540 |
Why?
|
| Disease Notification | 1 | 2017 | 9 | 0.540 |
Why?
|
| Hospitalists | 1 | 2018 | 46 | 0.540 |
Why?
|
| Epidemiological Monitoring | 1 | 2017 | 63 | 0.530 |
Why?
|
| Patients | 1 | 2018 | 127 | 0.520 |
Why?
|
| Enterococcus | 3 | 2019 | 31 | 0.520 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2019 | 480 | 0.510 |
Why?
|
| Mass Screening | 2 | 2019 | 833 | 0.510 |
Why?
|
| Attitude to Health | 1 | 2018 | 262 | 0.500 |
Why?
|
| Long-Term Care | 5 | 2021 | 73 | 0.500 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2017 | 152 | 0.500 |
Why?
|
| Medical Overuse | 1 | 2016 | 26 | 0.500 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 5 | 2024 | 45 | 0.500 |
Why?
|
| Formative Feedback | 1 | 2016 | 32 | 0.500 |
Why?
|
| United States Department of Veterans Affairs | 4 | 2018 | 715 | 0.490 |
Why?
|
| Documentation | 2 | 2016 | 122 | 0.490 |
Why?
|
| Lactobacillus | 2 | 2014 | 47 | 0.490 |
Why?
|
| Prevalence | 10 | 2022 | 2678 | 0.480 |
Why?
|
| Bacterial Infections | 3 | 2023 | 328 | 0.480 |
Why?
|
| Pseudomonas aeruginosa | 2 | 2017 | 180 | 0.470 |
Why?
|
| Urinary Bladder | 2 | 2022 | 252 | 0.470 |
Why?
|
| Ciprofloxacin | 4 | 2024 | 69 | 0.460 |
Why?
|
| Clinical Competence | 5 | 2014 | 1069 | 0.460 |
Why?
|
| Breast Neoplasms | 2 | 2018 | 2753 | 0.460 |
Why?
|
| Biodiversity | 1 | 2015 | 89 | 0.450 |
Why?
|
| Chronic Disease | 2 | 2023 | 1253 | 0.450 |
Why?
|
| Prospective Studies | 12 | 2021 | 6585 | 0.440 |
Why?
|
| Information Storage and Retrieval | 1 | 2015 | 66 | 0.440 |
Why?
|
| Extraintestinal Pathogenic Escherichia coli | 3 | 2021 | 25 | 0.440 |
Why?
|
| Feedback | 4 | 2024 | 167 | 0.430 |
Why?
|
| Models, Theoretical | 1 | 2016 | 395 | 0.420 |
Why?
|
| Diabetes Mellitus | 2 | 2024 | 934 | 0.420 |
Why?
|
| Risk Assessment | 7 | 2025 | 3725 | 0.420 |
Why?
|
| Risk Factors | 11 | 2025 | 10968 | 0.410 |
Why?
|
| Decision Support Systems, Clinical | 4 | 2020 | 203 | 0.400 |
Why?
|
| Medication Therapy Management | 1 | 2013 | 27 | 0.400 |
Why?
|
| Patient Reported Outcome Measures | 3 | 2020 | 213 | 0.390 |
Why?
|
| Pseudomonas Phages | 1 | 2012 | 10 | 0.390 |
Why?
|
| Heart-Assist Devices | 1 | 2021 | 1099 | 0.390 |
Why?
|
| Fimbriae, Bacterial | 2 | 2011 | 44 | 0.390 |
Why?
|
| Diagnostic Techniques, Urological | 1 | 2011 | 6 | 0.370 |
Why?
|
| Thrombelastography | 3 | 2021 | 59 | 0.370 |
Why?
|
| Diabetic Foot | 3 | 2020 | 167 | 0.370 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 4 | 2022 | 151 | 0.370 |
Why?
|
| Microbial Sensitivity Tests | 7 | 2024 | 836 | 0.360 |
Why?
|
| Health Services Research | 2 | 2020 | 190 | 0.360 |
Why?
|
| Nanostructures | 1 | 2011 | 65 | 0.360 |
Why?
|
| Epidemiologic Methods | 1 | 2011 | 102 | 0.360 |
Why?
|
| Ambulatory Care | 2 | 2025 | 416 | 0.350 |
Why?
|
| Microbiota | 2 | 2021 | 440 | 0.350 |
Why?
|
| Nitrofurazone | 1 | 2010 | 1 | 0.350 |
Why?
|
| Endocarditis | 1 | 2012 | 107 | 0.350 |
Why?
|
| Silver | 1 | 2010 | 30 | 0.340 |
Why?
|
| Patient Education as Topic | 5 | 2020 | 466 | 0.340 |
Why?
|
| Rhodobacteraceae | 1 | 2010 | 1 | 0.340 |
Why?
|
| Prostheses and Implants | 1 | 2012 | 153 | 0.340 |
Why?
|
| Urology | 1 | 2011 | 86 | 0.340 |
Why?
|
| Medication Adherence | 3 | 2025 | 340 | 0.330 |
Why?
|
| Abdomen | 2 | 2021 | 136 | 0.330 |
Why?
|
| Urinary Bladder, Neurogenic | 2 | 2009 | 46 | 0.330 |
Why?
|
| Uropathogenic Escherichia coli | 2 | 2022 | 21 | 0.320 |
Why?
|
| Case-Control Studies | 5 | 2025 | 3448 | 0.320 |
Why?
|
| Microbial Viability | 3 | 2021 | 43 | 0.320 |
Why?
|
| Medication Errors | 1 | 2011 | 207 | 0.310 |
Why?
|
| Clostridium Infections | 1 | 2013 | 251 | 0.310 |
Why?
|
| Blood | 4 | 2021 | 107 | 0.310 |
Why?
|
| Endocarditis, Bacterial | 1 | 2010 | 137 | 0.300 |
Why?
|
| Efficiency | 2 | 2020 | 70 | 0.300 |
Why?
|
| Biomedical Research | 1 | 2015 | 554 | 0.300 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2020 | 135 | 0.290 |
Why?
|
| Heart Failure | 1 | 2021 | 2428 | 0.280 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2013 | 270 | 0.280 |
Why?
|
| Texas | 9 | 2024 | 3668 | 0.270 |
Why?
|
| Proteus | 1 | 2006 | 7 | 0.270 |
Why?
|
| Central Venous Catheters | 2 | 2020 | 48 | 0.270 |
Why?
|
| Proteus Infections | 1 | 2006 | 7 | 0.270 |
Why?
|
| Urinary Calculi | 1 | 2006 | 18 | 0.260 |
Why?
|
| Bacteriological Techniques | 3 | 2019 | 90 | 0.260 |
Why?
|
| Hypersensitivity, Delayed | 1 | 2007 | 33 | 0.260 |
Why?
|
| Communication | 4 | 2025 | 541 | 0.260 |
Why?
|
| Paresis | 1 | 2007 | 33 | 0.260 |
Why?
|
| Aortic Valve | 1 | 2010 | 465 | 0.260 |
Why?
|
| Catheterization | 2 | 2008 | 238 | 0.260 |
Why?
|
| Staphylococcus aureus | 4 | 2021 | 480 | 0.260 |
Why?
|
| Skin Tests | 1 | 2007 | 80 | 0.250 |
Why?
|
| Antibodies, Viral | 4 | 2025 | 1206 | 0.250 |
Why?
|
| Fever | 2 | 2021 | 312 | 0.250 |
Why?
|
| Functional Laterality | 1 | 2007 | 196 | 0.250 |
Why?
|
| Chlorhexidine | 2 | 2004 | 49 | 0.240 |
Why?
|
| Internal Medicine | 3 | 2017 | 159 | 0.240 |
Why?
|
| Colicins | 1 | 2005 | 4 | 0.240 |
Why?
|
| Escherichia coli K12 | 1 | 2005 | 3 | 0.240 |
Why?
|
| Anti-Infective Agents, Local | 2 | 2004 | 71 | 0.240 |
Why?
|
| Vital Signs | 1 | 2025 | 27 | 0.240 |
Why?
|
| Cohort Studies | 4 | 2018 | 5206 | 0.230 |
Why?
|
| Disease Management | 2 | 2019 | 568 | 0.230 |
Why?
|
| Patient Discharge | 2 | 2021 | 520 | 0.230 |
Why?
|
| Cross-Sectional Studies | 7 | 2024 | 3758 | 0.230 |
Why?
|
| Immunization, Passive | 1 | 2025 | 129 | 0.230 |
Why?
|
| Point-of-Care Testing | 1 | 2025 | 33 | 0.230 |
Why?
|
| Surgeons | 2 | 2020 | 285 | 0.230 |
Why?
|
| Decision Support Techniques | 2 | 2021 | 318 | 0.220 |
Why?
|
| Gammaproteobacteria | 1 | 2024 | 23 | 0.210 |
Why?
|
| Spinal Cord Diseases | 1 | 2023 | 36 | 0.210 |
Why?
|
| Delivery of Health Care | 2 | 2022 | 682 | 0.210 |
Why?
|
| Recurrence | 3 | 2019 | 1469 | 0.210 |
Why?
|
| Prescriptions | 1 | 2023 | 43 | 0.210 |
Why?
|
| Diagnosis, Differential | 3 | 2017 | 1973 | 0.210 |
Why?
|
| Physician-Patient Relations | 2 | 2025 | 447 | 0.200 |
Why?
|
| 2-Propanol | 1 | 2002 | 3 | 0.200 |
Why?
|
| Antisepsis | 1 | 2002 | 8 | 0.190 |
Why?
|
| Point-of-Care Systems | 1 | 2025 | 194 | 0.190 |
Why?
|
| Insurance, Health | 1 | 2023 | 145 | 0.190 |
Why?
|
| Iodine | 1 | 2002 | 25 | 0.190 |
Why?
|
| Reproducibility of Results | 3 | 2020 | 3042 | 0.190 |
Why?
|
| Blood Specimen Collection | 1 | 2002 | 48 | 0.190 |
Why?
|
| Interleukin-6 | 1 | 2024 | 439 | 0.190 |
Why?
|
| Pericarditis, Tuberculous | 1 | 2001 | 1 | 0.180 |
Why?
|
| Gram-Negative Bacteria | 1 | 2022 | 74 | 0.180 |
Why?
|
| Postoperative Period | 2 | 2021 | 336 | 0.180 |
Why?
|
| Critical Illness | 3 | 2021 | 628 | 0.180 |
Why?
|
| Return to Work | 1 | 2021 | 11 | 0.180 |
Why?
|
| Bacteria | 4 | 2023 | 534 | 0.180 |
Why?
|
| Health Literacy | 2 | 2024 | 78 | 0.180 |
Why?
|
| Language | 1 | 2023 | 223 | 0.180 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2015 | 402 | 0.180 |
Why?
|
| Viral Tail Proteins | 1 | 2021 | 6 | 0.180 |
Why?
|
| Heparan Sulfate Proteoglycans | 1 | 2021 | 17 | 0.180 |
Why?
|
| Microbial Interactions | 1 | 2021 | 17 | 0.170 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2001 | 138 | 0.170 |
Why?
|
| Communicable Diseases | 1 | 2023 | 164 | 0.170 |
Why?
|
| Career Choice | 1 | 2022 | 163 | 0.170 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2002 | 237 | 0.170 |
Why?
|
| Guidelines as Topic | 2 | 2019 | 202 | 0.170 |
Why?
|
| Quality Improvement | 2 | 2016 | 701 | 0.160 |
Why?
|
| Thrombophilia | 1 | 2020 | 42 | 0.160 |
Why?
|
| Polysaccharides | 1 | 2021 | 152 | 0.160 |
Why?
|
| Influenza Vaccines | 1 | 2004 | 498 | 0.160 |
Why?
|
| Autoimmune Diseases | 1 | 2002 | 278 | 0.160 |
Why?
|
| Observational Studies as Topic | 1 | 2020 | 107 | 0.160 |
Why?
|
| Residence Characteristics | 1 | 2022 | 290 | 0.160 |
Why?
|
| Sepsis | 1 | 2004 | 522 | 0.160 |
Why?
|
| Female Urogenital Diseases | 1 | 2019 | 8 | 0.150 |
Why?
|
| Emergency Service, Hospital | 3 | 2024 | 1166 | 0.150 |
Why?
|
| Male Urogenital Diseases | 1 | 2019 | 16 | 0.150 |
Why?
|
| Skin | 1 | 2002 | 546 | 0.150 |
Why?
|
| Thoracic Surgery | 1 | 2021 | 166 | 0.150 |
Why?
|
| Data Mining | 2 | 2016 | 60 | 0.150 |
Why?
|
| Recovery of Function | 1 | 2021 | 463 | 0.150 |
Why?
|
| Workflow | 1 | 2019 | 135 | 0.150 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2020 | 138 | 0.150 |
Why?
|
| Activities of Daily Living | 1 | 2021 | 430 | 0.150 |
Why?
|
| Employee Performance Appraisal | 1 | 2018 | 12 | 0.150 |
Why?
|
| Urination Disorders | 1 | 2018 | 21 | 0.150 |
Why?
|
| Relative Value Scales | 1 | 2018 | 12 | 0.150 |
Why?
|
| Antiviral Agents | 1 | 2024 | 824 | 0.150 |
Why?
|
| Time Factors | 4 | 2020 | 6544 | 0.150 |
Why?
|
| Gastrointestinal Tract | 1 | 2021 | 242 | 0.150 |
Why?
|
| Stroke | 1 | 2007 | 1078 | 0.150 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2018 | 35 | 0.140 |
Why?
|
| Coliphages | 1 | 2018 | 6 | 0.140 |
Why?
|
| Bacteriolysis | 1 | 2018 | 8 | 0.140 |
Why?
|
| Diagnosis-Related Groups | 1 | 2018 | 28 | 0.140 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2013 | 128 | 0.140 |
Why?
|
| Safety Management | 1 | 2019 | 121 | 0.140 |
Why?
|
| Siderophores | 1 | 2017 | 10 | 0.140 |
Why?
|
| Patient Participation | 1 | 2020 | 240 | 0.140 |
Why?
|
| Patient-Centered Care | 1 | 2020 | 237 | 0.140 |
Why?
|
| DNA, Bacterial | 2 | 2010 | 496 | 0.140 |
Why?
|
| Minocycline | 2 | 2008 | 42 | 0.140 |
Why?
|
| Patient Satisfaction | 2 | 2020 | 489 | 0.140 |
Why?
|
| Gastric Mucosa | 1 | 2021 | 493 | 0.140 |
Why?
|
| Aortic Rupture | 1 | 2019 | 124 | 0.140 |
Why?
|
| Biopsy | 2 | 2019 | 1298 | 0.140 |
Why?
|
| Audiovisual Aids | 1 | 2017 | 24 | 0.140 |
Why?
|
| Metals | 1 | 2018 | 66 | 0.140 |
Why?
|
| Homes for the Aged | 1 | 2017 | 26 | 0.140 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2001 | 409 | 0.130 |
Why?
|
| Research | 1 | 2019 | 273 | 0.130 |
Why?
|
| Anti-Infective Agents, Urinary | 1 | 2016 | 8 | 0.130 |
Why?
|
| Acetylcysteine | 2 | 2008 | 84 | 0.130 |
Why?
|
| Propensity Score | 1 | 2018 | 263 | 0.130 |
Why?
|
| Health Care Surveys | 1 | 2018 | 295 | 0.130 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2017 | 89 | 0.130 |
Why?
|
| Acute Disease | 2 | 2017 | 1183 | 0.130 |
Why?
|
| Bone and Bones | 1 | 2019 | 306 | 0.130 |
Why?
|
| Colony Count, Microbial | 2 | 2009 | 89 | 0.130 |
Why?
|
| Americas | 1 | 2016 | 52 | 0.130 |
Why?
|
| Goals | 1 | 2017 | 134 | 0.130 |
Why?
|
| Databases, Factual | 2 | 2019 | 1257 | 0.130 |
Why?
|
| Motivation | 1 | 2018 | 329 | 0.120 |
Why?
|
| Secondary Prevention | 1 | 2017 | 223 | 0.120 |
Why?
|
| Linear Models | 1 | 2018 | 720 | 0.120 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 1468 | 0.120 |
Why?
|
| Cost of Illness | 1 | 2018 | 277 | 0.120 |
Why?
|
| Data Collection | 3 | 2013 | 395 | 0.120 |
Why?
|
| Leg | 1 | 2016 | 142 | 0.120 |
Why?
|
| Professional Competence | 1 | 2016 | 96 | 0.120 |
Why?
|
| Health Care Costs | 1 | 2019 | 409 | 0.120 |
Why?
|
| Treatment Outcome | 5 | 2025 | 13089 | 0.120 |
Why?
|
| Veterans Health | 1 | 2017 | 180 | 0.120 |
Why?
|
| Program Development | 1 | 2016 | 190 | 0.120 |
Why?
|
| Faculty, Medical | 1 | 2018 | 281 | 0.120 |
Why?
|
| Utilization Review | 1 | 2015 | 41 | 0.120 |
Why?
|
| Mannose | 2 | 2011 | 27 | 0.110 |
Why?
|
| Education, Medical, Graduate | 1 | 2020 | 567 | 0.110 |
Why?
|
| Chi-Square Distribution | 2 | 2008 | 596 | 0.110 |
Why?
|
| Patient Care Team | 1 | 2019 | 578 | 0.110 |
Why?
|
| Caregivers | 1 | 2020 | 594 | 0.110 |
Why?
|
| Curriculum | 1 | 2020 | 766 | 0.110 |
Why?
|
| Surface Properties | 2 | 2011 | 96 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 384 | 0.110 |
Why?
|
| Adaptation, Psychological | 1 | 2018 | 453 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 395 | 0.110 |
Why?
|
| Drug Prescriptions | 1 | 2016 | 244 | 0.110 |
Why?
|
| Corynebacterium | 1 | 2014 | 12 | 0.110 |
Why?
|
| Social Norms | 1 | 2014 | 5 | 0.110 |
Why?
|
| Pregnancy | 5 | 2024 | 7591 | 0.110 |
Why?
|
| Staphylococcus | 1 | 2014 | 69 | 0.110 |
Why?
|
| Young Adult | 4 | 2024 | 9967 | 0.110 |
Why?
|
| Quality of Health Care | 1 | 2017 | 424 | 0.110 |
Why?
|
| Reference Standards | 1 | 2015 | 245 | 0.110 |
Why?
|
| Double-Blind Method | 3 | 2022 | 1654 | 0.110 |
Why?
|
| Candida | 1 | 2014 | 84 | 0.100 |
Why?
|
| Intermittent Urethral Catheterization | 1 | 2013 | 9 | 0.100 |
Why?
|
| Referral and Consultation | 1 | 2017 | 573 | 0.100 |
Why?
|
| Withholding Treatment | 1 | 2013 | 70 | 0.100 |
Why?
|
| Adolescent | 4 | 2019 | 20586 | 0.100 |
Why?
|
| Pilot Projects | 3 | 2021 | 1463 | 0.100 |
Why?
|
| Self Efficacy | 1 | 2014 | 210 | 0.100 |
Why?
|
| Educational Status | 1 | 2014 | 296 | 0.100 |
Why?
|
| Venous Thromboembolism | 1 | 2015 | 187 | 0.100 |
Why?
|
| Quadriplegia | 2 | 2025 | 38 | 0.100 |
Why?
|
| Neutropenia | 3 | 2019 | 205 | 0.100 |
Why?
|
| Quality of Life | 2 | 2021 | 2160 | 0.100 |
Why?
|
| Qualitative Research | 3 | 2020 | 659 | 0.090 |
Why?
|
| Peripheral Arterial Disease | 1 | 2016 | 321 | 0.090 |
Why?
|
| Paraplegia | 2 | 2025 | 93 | 0.090 |
Why?
|
| Photoelectron Spectroscopy | 1 | 2011 | 7 | 0.090 |
Why?
|
| Comorbidity | 1 | 2017 | 1625 | 0.090 |
Why?
|
| Device Removal | 1 | 2013 | 224 | 0.090 |
Why?
|
| Silicon | 1 | 2010 | 12 | 0.090 |
Why?
|
| Fibrinolysis | 2 | 2021 | 44 | 0.090 |
Why?
|
| Alkynes | 1 | 2010 | 26 | 0.090 |
Why?
|
| Phenazines | 1 | 2010 | 9 | 0.090 |
Why?
|
| Gentian Violet | 1 | 2010 | 8 | 0.080 |
Why?
|
| Telemedicine | 1 | 2017 | 507 | 0.080 |
Why?
|
| DNA, Ribosomal | 1 | 2010 | 57 | 0.080 |
Why?
|
| HIV Infections | 2 | 2013 | 2023 | 0.080 |
Why?
|
| Patient Safety | 1 | 2015 | 437 | 0.080 |
Why?
|
| Anticoagulants | 3 | 2021 | 628 | 0.080 |
Why?
|
| Feasibility Studies | 2 | 2025 | 823 | 0.080 |
Why?
|
| Education, Medical | 1 | 2014 | 306 | 0.080 |
Why?
|
| Patient Compliance | 1 | 2013 | 475 | 0.080 |
Why?
|
| Vancomycin | 1 | 2012 | 236 | 0.080 |
Why?
|
| Microscopy | 1 | 2010 | 124 | 0.080 |
Why?
|
| Polyamines | 1 | 2009 | 31 | 0.080 |
Why?
|
| Thrombolytic Therapy | 2 | 2021 | 214 | 0.080 |
Why?
|
| Cluster Analysis | 1 | 2010 | 437 | 0.080 |
Why?
|
| Silicones | 1 | 2008 | 33 | 0.070 |
Why?
|
| Operon | 1 | 2008 | 54 | 0.070 |
Why?
|
| Postoperative Complications | 1 | 2020 | 3168 | 0.070 |
Why?
|
| Polyethylene Glycols | 1 | 2009 | 253 | 0.070 |
Why?
|
| Phylogeny | 1 | 2010 | 777 | 0.070 |
Why?
|
| Sensitivity and Specificity | 2 | 2025 | 2153 | 0.070 |
Why?
|
| Plasmids | 1 | 2008 | 528 | 0.070 |
Why?
|
| Hypertension | 1 | 2016 | 1399 | 0.070 |
Why?
|
| Transplant Recipients | 2 | 2019 | 227 | 0.070 |
Why?
|
| Equipment Contamination | 1 | 2007 | 41 | 0.060 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2011 | 490 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 2 | 2021 | 1085 | 0.060 |
Why?
|
| Leadership | 2 | 2020 | 247 | 0.060 |
Why?
|
| Immunity, Cellular | 1 | 2007 | 206 | 0.060 |
Why?
|
| Drug Combinations | 2 | 2007 | 281 | 0.060 |
Why?
|
| Patient Readmission | 2 | 2021 | 427 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2025 | 1252 | 0.060 |
Why?
|
| Age Factors | 2 | 2019 | 2955 | 0.060 |
Why?
|
| Molecular Sequence Data | 1 | 2010 | 3962 | 0.060 |
Why?
|
| Common Cold | 1 | 2024 | 24 | 0.060 |
Why?
|
| Prescription Drug Overuse | 1 | 2024 | 4 | 0.060 |
Why?
|
| Hemagglutination Inhibition Tests | 1 | 2004 | 114 | 0.060 |
Why?
|
| Trauma Severity Indices | 1 | 2004 | 87 | 0.060 |
Why?
|
| Pharyngitis | 1 | 2024 | 34 | 0.060 |
Why?
|
| Silver Sulfadiazine | 1 | 2004 | 9 | 0.060 |
Why?
|
| ROC Curve | 1 | 2006 | 604 | 0.050 |
Why?
|
| Injections, Intramuscular | 1 | 2004 | 197 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 1 | 2010 | 1827 | 0.050 |
Why?
|
| Vaccines, Inactivated | 1 | 2004 | 148 | 0.050 |
Why?
|
| Drug Resistance, Multiple | 1 | 2024 | 54 | 0.050 |
Why?
|
| Antibody Formation | 1 | 2004 | 275 | 0.050 |
Why?
|
| Influenza A virus | 1 | 2004 | 152 | 0.050 |
Why?
|
| Providencia | 1 | 2003 | 3 | 0.050 |
Why?
|
| Catheterization, Central Venous | 2 | 2020 | 139 | 0.050 |
Why?
|
| Mice | 4 | 2022 | 18910 | 0.050 |
Why?
|
| Child | 4 | 2019 | 25874 | 0.050 |
Why?
|
| Antigens, Viral | 1 | 2024 | 440 | 0.050 |
Why?
|
| Diarrhea | 1 | 2024 | 343 | 0.050 |
Why?
|
| Pharmacists | 1 | 2023 | 105 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2023 | 310 | 0.050 |
Why?
|
| Intention | 2 | 2013 | 101 | 0.050 |
Why?
|
| Candidiasis | 1 | 2003 | 138 | 0.050 |
Why?
|
| RNA, Viral | 1 | 2024 | 563 | 0.050 |
Why?
|
| Opportunistic Infections | 1 | 2002 | 80 | 0.050 |
Why?
|
| Animals | 5 | 2022 | 36121 | 0.050 |
Why?
|
| Renal Dialysis | 1 | 2008 | 892 | 0.040 |
Why?
|
| Antibodies, Neutralizing | 1 | 2025 | 498 | 0.040 |
Why?
|
| Medication Reconciliation | 1 | 2021 | 17 | 0.040 |
Why?
|
| Adaptation, Biological | 1 | 2021 | 36 | 0.040 |
Why?
|
| Genetic Fitness | 1 | 2021 | 37 | 0.040 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2021 | 62 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2022 | 241 | 0.040 |
Why?
|
| Pericardial Effusion | 1 | 2001 | 70 | 0.040 |
Why?
|
| beta-Lactamases | 1 | 2023 | 212 | 0.040 |
Why?
|
| Drug Antagonism | 1 | 2020 | 13 | 0.040 |
Why?
|
| Reflex | 1 | 2020 | 34 | 0.040 |
Why?
|
| Hospitals, Religious | 1 | 2020 | 6 | 0.040 |
Why?
|
| In Vitro Techniques | 1 | 2002 | 958 | 0.040 |
Why?
|
| Catholicism | 1 | 2020 | 6 | 0.040 |
Why?
|
| Coronavirus | 1 | 2020 | 27 | 0.040 |
Why?
|
| Symbiosis | 1 | 2021 | 102 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2020 | 239 | 0.040 |
Why?
|
| Professional-Patient Relations | 1 | 2020 | 93 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2021 | 750 | 0.040 |
Why?
|
| Models, Organizational | 1 | 2019 | 44 | 0.040 |
Why?
|
| Aftercare | 1 | 2021 | 156 | 0.040 |
Why?
|
| Cell Culture Techniques | 1 | 2021 | 295 | 0.040 |
Why?
|
| Virulence Factors | 1 | 2021 | 187 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2022 | 804 | 0.040 |
Why?
|
| Postoperative Care | 1 | 2021 | 312 | 0.040 |
Why?
|
| Syndrome | 1 | 2002 | 1173 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2020 | 313 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2025 | 1053 | 0.040 |
Why?
|
| Vaccination | 1 | 2004 | 1019 | 0.040 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2020 | 194 | 0.040 |
Why?
|
| Interinstitutional Relations | 1 | 2018 | 21 | 0.040 |
Why?
|
| Bacterial Load | 1 | 2018 | 35 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2019 | 429 | 0.040 |
Why?
|
| Organoids | 1 | 2021 | 301 | 0.030 |
Why?
|
| Colorectal Surgery | 1 | 2017 | 10 | 0.030 |
Why?
|
| Colostomy | 1 | 2017 | 28 | 0.030 |
Why?
|
| Biosynthetic Pathways | 1 | 2017 | 28 | 0.030 |
Why?
|
| Molecular Conformation | 1 | 2017 | 112 | 0.030 |
Why?
|
| Wound Healing | 1 | 2021 | 486 | 0.030 |
Why?
|
| Bacterial Translocation | 1 | 2017 | 24 | 0.030 |
Why?
|
| Practice Management, Medical | 1 | 2016 | 11 | 0.030 |
Why?
|
| Colectomy | 1 | 2017 | 84 | 0.030 |
Why?
|
| Nursing Staff | 1 | 2016 | 15 | 0.030 |
Why?
|
| Preventive Health Services | 1 | 2017 | 61 | 0.030 |
Why?
|
| Marfan Syndrome | 1 | 2019 | 150 | 0.030 |
Why?
|
| Virulence | 1 | 2017 | 279 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2018 | 233 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 305 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2018 | 4766 | 0.030 |
Why?
|
| Focus Groups | 1 | 2017 | 215 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2018 | 809 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2020 | 539 | 0.030 |
Why?
|
| User-Computer Interface | 1 | 2017 | 167 | 0.030 |
Why?
|
| Genome, Viral | 1 | 2017 | 184 | 0.030 |
Why?
|
| Vocabulary, Controlled | 1 | 2015 | 13 | 0.030 |
Why?
|
| Utah | 1 | 2015 | 83 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 336 | 0.030 |
Why?
|
| Datasets as Topic | 1 | 2015 | 105 | 0.030 |
Why?
|
| Cryoelectron Microscopy | 1 | 2017 | 246 | 0.030 |
Why?
|
| Pneumonia | 1 | 2019 | 341 | 0.030 |
Why?
|
| Biomarkers | 1 | 2025 | 3417 | 0.030 |
Why?
|
| Thrombosis | 1 | 2020 | 544 | 0.030 |
Why?
|
| Decision Making | 1 | 2020 | 702 | 0.030 |
Why?
|
| Escherichia coli Proteins | 1 | 2017 | 316 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 306 | 0.030 |
Why?
|
| Iron | 1 | 2017 | 303 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2017 | 1146 | 0.030 |
Why?
|
| Staphylococcal Infections | 1 | 2019 | 573 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2019 | 1097 | 0.030 |
Why?
|
| Health Policy | 1 | 2015 | 233 | 0.020 |
Why?
|
| Base Sequence | 1 | 2017 | 3156 | 0.020 |
Why?
|
| Pandemics | 1 | 2020 | 1195 | 0.020 |
Why?
|
| Machine Learning | 1 | 2015 | 348 | 0.020 |
Why?
|
| Logistic Models | 1 | 2016 | 1870 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2012 | 237 | 0.020 |
Why?
|
| Alkylation | 1 | 2010 | 10 | 0.020 |
Why?
|
| Microscopy, Atomic Force | 1 | 2010 | 20 | 0.020 |
Why?
|
| Infant | 1 | 2006 | 13254 | 0.020 |
Why?
|
| Incidence | 1 | 2018 | 3393 | 0.020 |
Why?
|
| Obesity | 1 | 2022 | 2438 | 0.020 |
Why?
|
| Aging | 1 | 2017 | 1270 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2006 | 14895 | 0.020 |
Why?
|
| Biosensing Techniques | 1 | 2010 | 69 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2010 | 238 | 0.020 |
Why?
|
| Self Report | 1 | 2013 | 553 | 0.020 |
Why?
|
| Anti-HIV Agents | 1 | 2013 | 343 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2010 | 324 | 0.020 |
Why?
|
| Dendrimers | 1 | 2009 | 10 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2009 | 71 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2022 | 8633 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 5451 | 0.020 |
Why?
|
| Cell Death | 1 | 2009 | 247 | 0.020 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2008 | 80 | 0.020 |
Why?
|
| Pediatrics | 1 | 2017 | 1218 | 0.020 |
Why?
|
| Epithelium, Corneal | 1 | 2009 | 171 | 0.020 |
Why?
|
| Staphylococcus epidermidis | 1 | 2007 | 40 | 0.020 |
Why?
|
| Cell Survival | 1 | 2009 | 886 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2009 | 937 | 0.010 |
Why?
|
| Cell Line | 1 | 2009 | 2859 | 0.010 |
Why?
|